We confirmed common AD tau phosphorylation sites across epilepsy pathologies, with more consistent labeling with AT8 and CP13 compared to PHF1, AT100, and AT180, the later epitopes showing more variability (Figure S4); for example, PHF1 and AT180 were relatively low in SWS and cavernoma. This evidence concerns the gene MAPT and cavernous hemangioma.